哈三联：10月23日召开董事会会议

Group 1 - The company Harsanlian (SZ 002900) held its 26th meeting of the fourth board of directors on October 23, 2025, via telecommunication to discuss the appointment of the accounting firm for the year 2025 [1] - For the first half of 2025, Harsanlian's revenue composition was as follows: 86.08% from the pharmaceutical industry, 10.26% from other businesses, 2.55% from veterinary medicine, 0.94% from cosmetics, and 0.16% from functional foods [1] - As of the report date, Harsanlian's market capitalization was 4.5 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - The secondary market for biopharmaceuticals is currently thriving, while the primary market is experiencing a cooling in fundraising [1]